WalterK.KraftMDMS, FACP

PubMed

• 5 citations
  Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial.
  Gary Peltz, Lauren M Jansson, Susan Adeniyi-Jones, Carol Cohane, David Drover
  Journal of Perinatology. 2023-03-01
• 30 citations
  Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers.
  Srikanth Nagalla, Lynda Thomson, Yaa Oppong, Brendan Bachman, Inna Chervoneva
  Clinical and Translational Science. 2016-06-01
• 44 citations
  Prevalence of obstructive lung disease in HIV population: a cross sectional study.
  Amyn Hirani, Rodrigo Cavallazzi, Tajender S. Vasu, Monvasi Pachinburavan, Walter K. Kraft
  Respiratory Medicine. 2011-11-01

Journal Articles

• “How to Help Your Patients Quit Smoking”  
  Kraft W, Steinberg M, Delnevo C., IM: Internal Medicine, 3/1/1999

Books/Book Chapters

• Medical Management of the Surgical Patient 
  Chapter: “Managing Medication in the Perioperative Period” 
  Kraft WK, Diemer GEditors: Merli G, Weitz H.Saunders, Philadelphia, PAEdition 3rd,2008
• Pharmacology and Therapeutics: Principles to Practice 
  Chapter: Asthma and COPD. 
  Kraft WK, Leone FEditors: Waldman SA, Terzic A.Saunders ElsevierEdition 1st,2008
• Pharmacology and Therapeutics: Principles to Practice 
  Chapter: Peptic Ulcer Disease and Reflux. 
  Mejia A, Kraft WKEditors: Waldman SA, Terzic A.Saunders ElsevierEdition 1st,2008
• Clinical Immunology and Allergy in Medicine 
  Chapter: “Effects of Concomitant Administration of an Aluminum- and Magnesium-containing Antacid on the Absorption Profile of Loratadine”, Chapter 97 
  Greenberg HE , Mehdi F, VanBuren S, Waldman SA, Pequignot E, Kraft WKEditors: Marone G.JGC, Naples, Italy2003
• Essential Evidence Plus 
  Chapter: Asthma, Chronic Treatment. 
  Kraft WK, Desimone DCEditors: Ebell MH.John Wiley and Sons, Hoboken, NJEdition 1st,
• Essential Evidence Plus 
  Chapter: Neonatal Abstinence Syndrome. 
  Kraft WKEditors: Ebell MH.John Wiley and Sons, Hoboken, NJEdition 1st,
• Essential Evidence Plus 
  Chapter: Opioid Overdose. 
  Kraft WKEditors: Ebell MH.John Wiley and Sons, Hoboken, NJEdition 1st,
• Join now to see all

Abstracts/Posters

• Ethanol Pharmacokinetics in Neonates Secondary to Medication Administration
  Marek E, Adeniyi-Jones SC, Roke L, DeCerbo TE, Cordell RL, Monks PS, Kraft WK, American Academy of Pediatrics, Washington, DC, 10/2015
• No Evidence of a Drug-Drug Interaction between Letermovir (MK-8228) and Mycophenolate Mofetil.
  Marshall WL, Badshah C, Liu F, Kraft WK, Gonzales-Colon F, van Schanke A, Udo de Haes J, Kantesaria B, Cho C, Hulskotte E, Butterton JR, Marcantonio EE., ASMBT, San Diego, 2/2015
• Neonatal abstinence syndrome (NAS) in methadone exposed infants: role of genetic variability.
  Fielder AL, Coller JK., Hutchinson M, Haslam RR, Lu N, Adeniyi-Jones S, Ehrlich M, Kraft WK, Accepted for presentation at CPDD Scientific Meeting, 6/18/2014
• Effect of Ritonavir (RTV) and Tenofovir (TDF) on the Pharmacokinetics of MK-1439, a Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI).
  Anderson MS, Gilmartin J, Mitselos A, Laethem T, van Bortel L, Kraft WK, Guo Y, Dockendorf MF, Wagner JA, Butteron JR, Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC 2013), Denver, CO, 10/11/2013
• Developing a Transition of Care Model to Safely and Effectively Manage Complex Vascular Diseases.
  Palladino M, Thomson L, Eraso EH, Merli G, Galanis T, Kraft WK , Perez A, The Anticoagulation Forum, Phoenix, AZ, 5/5/2013
• The Impact of Community Use of Novel Oral Anticoagulants on an Academic Medical Center.
  Eraso EH, Galanis T, Kipp K, Kraft WK , Palladino M, Perez A, Ferebee–Spruill K, Merli G, Swift B, Thomson L, Vining B, The Anticoagulation Forum, Phoenix, AZ, 5/5/2013
• A Potential Interaction between Melatonin and Warfarin: Is It Worth Losing Sleep Over?
  D’Ascenzo JD, Franta KJ, Kraft WK, Thomson LJ, ASHP (American Society of Health System Pharmacists) Midyear Clinical Meeting, Las Vegas, NV, 12/5/2012
• Effect of Concomitant Medications Affecting Gastric pH and Motility on Posaconazole (POS) Tablet Pharmacokinetics (PK).
  Kraft WK, Chang P, van Iersel MLPS, Waskin H, Krishna G, Kersemaekers W, ICAAC meeting, San Francisco, CA, 9/1/2012
• Characterization of venous thromboembolism stratified by medical thromboprophylaxis: Experience in a free standing neurosciences hospital.
  Perez A, Galanis T, Eraso EH, Kraft WK, Templin M, Louis DZ, Merli GJ, Accepted for presentation at the Society for Vascular Medicine meeting, Minneapolis, MN, 6/14/2012
• Population pharmacokinetic modeling of buprenorphine in newborns with neonatal abstinence syndrome.
  Wu D, Kraft WK , Ehrlich ME, Dombrowsky E, Barrett JS, American Society for Clinical Pharmacology and Therapeutics meeting, Washington, DC, 3/1/2012
• Comparing Prognosis Estimates of Cancer Patients and Their Oncologists.
  Gentzler R, Kraft WK, Leiby B, Filicko-O'Hara J, 2012 ASCO Annual Meeting Proceedings I, 1/1/2012
• Safety and Tolerability of Single Dose Green Tea Extract Epigallocatechin Gallate (EGCG) in Cirrhotic and Non-cirrhotic Hepatitis C Patients.
  Halegoua-De Marzio D, Kraft WK, Greenbaum L, Xie Y, Hawke R, Navarro VN, Digestive Diseases Week Meeting, San Diego, CA, 1/1/2012
• “Comparison of Transdermal and Oral Estrogen Hormone Therapy and Risks of Venous Thromboembolic Events”
  Omicioli V, Daskalakis C, Louis D, Rabinowitz C, Maio V, Kraft WK, 20th Annual Meeting of the North American Menopause Society, San Diego, CA, 9/30/2009
• “BMS-790052 is a First-in Class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study.”
  Nettles RE, Chien C, Chung E, Persson A, Gao M, Belema M, Meanwell N, DeMicco M, Marbury T, Goldwater P, Northup P, Coumbis J, Kraft WK, Charlton M, Lopez-Talavera JC,..., 13th International Symposium on Viral Hepatitis and Liver Disease, Washington, DC, 3/1/2009
• "BMS-790052 is a First-in Class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study.”
  Nettles RE, Chien C, Chung E, Persson A, Gao M, Belema M, Meanwell N, DeMicco M, Marbury T, Goldwater P, Northup P, Coumbis J, Kraft WK, Charlton M, Lopez-Talavera JC,..., The Asian Pacific Association for the Study of the Liver Meeting, Hong Kong, 2/1/2009
• “BMS-790052 is a Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study"
  Nettles RE, Chien C, Chung E, Persson A, Gao M, Belema M, Meanwell N, DeMicco M, Marbury T, Goldwater P, Northup P, Coumbis J, Kraft WK, Charlton M, Lopez-Talavera JC,..., American Association for the Study of Liver Diseases meeting, San Francisco, CA, 11/1/2008
• “Laropiprant Does Not Alter the Antiplatelet Activity of Aspirin.”
  Schwartz J, Mabalot J, Luo L, Dallob A, Kraft WK, Wagner J, Lai E, American Heart Association meeting, New Orleans, LA, 11/1/2008
• "Safety, Tolerability and Antiviral Activity of MK-7009, a Novel Inhibitor of the Hepatitis C Virus NS3/4A Protease, in Patients with Chronic HCV Genotype 1 Infection.”
  Lawitz E, Sulkowski M, Jacobson I, Faruqui S, Kraft W, Maliakkal B, Al-Ibrahim, ReemGhalib M, Gordon S, Kwo P, Rockstroh J, Miller M, Hwang P, Gress J, Quirk E, American Association for the Study of Liver Diseases meeting, San Francisco, CA, 11/1/2008
• ”Sublingual bioavailability of buprenorphine in newborns with neonatal abstinence syndrome--a case study on physiological and developmental changes using SIMCYP.”
  Wu D, Kraft WK , Ehrlich ME, Barrett JS, American College of Clinical Pharmacology meeting, Philadelphia, PA, 9/1/2008
• "First Use of Sublingual Buprenorphine for Treatment of the Neonatal Abstinence Syndrome: A Randomized Trial.”
  Kraft WK , Dysart K, Gibson E, Greenspan J, Damle V, Kaltenbach K, LaRusso J, Moody D. Ehrlich M, Society for Pediatric Research Meeting, Hawaii, 5/1/2008
• ”Cough Response To Inhaled Capsaicin Following A Blinded, Oral, Single Dose Of Codeine, Dextromethorphan, Or Placebo In Healthy Males.”
  Gong JP, Burke J, Blanchard RL, Dicpinigaitis P, Yan X, Palcza J, Bradstreet TE, Kraft WK, Clinical Pharmacology and Therapeutics; Poster at the American Society for Clinical Pharmacology and Therapeutics meeting, Orlando, FL, 4/1/2008
• “Prophylaxis, screening and the incidence of periprocedural deep vein thrombosis among neurosurgical patients at an academic medical center”.
  Henwood PC, Merli GJ, Rosenwasser RH, Tzanis G, Thomson L, Fink J, Kraft WK, Society for Vascular Medicine and Biology's 18th Annual Scientific Sessions, Baltimore, MD, 6/1/2007
• “Low molecular weight heparin, the most cost effective treatment of venous thromboembolism”
  Hayes E, Almario C, Pizzi L, Kraft WK, Baxter J, Society for Maternal Fetal Medicine 27th Annual Scientific Meeting, San Francisco, CA, 2/1/2007
• The Pharmacokinetics Of Taurolidine Metabolites In Healthy Volunteers"
  Li G, Waldman SA, Greenberg HE, Kraft WK, Poster at the American College of Clinical Pharmacology meeting, Cambridge, MA, 9/1/2006
• ”Pharmacokinetics (PK) of Multiple Oral Doses of Desloratadine (DCL) and Fexofenadine (FEX) in a Population of Healthy Adults Identified Phenotypically as Desloratadin...
  Kraft WK, Blum RA, Frick GS, Vitow C, Stewart JA, Kovacs SJ, Clinical Pharmacology and Therapeutics; Poster at the American Society for Clinical Pharmacology and Therapeutics meeting, Orlando, FL, 3/1/2005
• Join now to see all

Lectures

• “How the IRB Looks at Medical Education Projects”. 
  Thomas Jefferson University/Hospital - 3/13/2014
• Speaker, “Pharmacologic Therapies for the Neonatal Abstinence Syndrome”. 
  Cincinnati Children’s Hospital, University of Cincinnati School of Medicine - 3/6/2014
• Faculty Speaker, "Toxidromes: Making the best treatment decisions" 
  1/22/2014
• "Challenges Facing Physician Scientists in the 21st Century" 
  Thomas Jefferson University/Hospital - 9/28/2013
• "How to Build a Career in Clinical Research” 
  Thomas Jefferson University/Hospital - 9/19/2013
• Faculty Speaker, "Examining the Evidence: Controversies in the Pharmacologic Management" 
  7/14/2013
• Speaker, "Controversies in the Treatment of Neonatal Abstinence Syndrome: Methadone, Morphine, Buprenorphine, Clonidine, Phenobarbital or Bust?" 
  Washington, DC - 5/30/2013
• Speaker, "Pharmacology Review: Risks and Benefits of Methadone, Morphine, Buprenorphine, Clonidine, and/or Phenobarbital". 
  Washington, DC - 5/29/2013
• Faculty Speaker, "Substance Exposure 101: Frequency and Neonatal Impact by Agent" 
  5/15/2013
• Speaker, "“Novel Therapies in Treatment of Neonatal Abstinence Syndrome" 
  Nemours/A.I. duPont Hospital for Children, Wilmington, DE - 2/25/2013
• Speaker, "Best Practices and Resources for Preventing Dual Enrollment in Clinical Trials" 
  New Brunswick, NJ - 11/16/2012
• Speaker and Discussant, "Bridging Adult and Pediatric Conditions: Biomarkers in Pediatric Drug Development" 
  Los Angeles, CA - 11/4/2012
• Speaker and Discussant, "Safety Challenges and Developing Models for Emergency Response Coverage in First in Human Trials" 
  San Diego, CA - 9/23/2012
• "Optimizing Pediatric Drug Development” 
  Thomas Jefferson University - 5/9/2012
• Speaker and Discussant, "Addressing Current Recruitment and Retention Challenges within Pediatric Clinical Trials" and "Optimizing Pediatric Drug Development" 
  Philadelphia, PA - 5/3/2012
• Speaker and Discussant, "The Human Research Participant in Today’s Early Phase Research & Updates on National Registry Initiatives" 
  Bethesda, MD - 4/26/2012
• Symposium Chair and Presenter, "Optimizing Pediatric Therapeutics by Applying Lessons from Adult Drug Development" 
  Washington, DC - 3/16/2012
• “Obtaining Industry Support of Investigator Initiated Research Proposals” 
  Thomas Jefferson University/Hospital - 1/10/2012
• Visiting Speaker, "Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome" 
  12/20/2011
• “New Agents, New Horizons in the Pharmacologic Management of Substance - Exposed Newborns” 
  Washington, DC - 6/1/2011
• "Phase 1 Research and Healthy Volunteers" 
  Cooper University Hospital, Camden, NJ - 2/24/2011
• Featured Speaker, “Future Trends in the Treatment of Neonatal Abstinence Syndrome” 
  Alexandria, VA - 6/24/2010
• “Venous Thromboembolism Prophylaxis in the Neurosurgical Patient” 
  Thomas Jefferson University/Hospital - 6/12/2009
• “Phase 1 Trials in Healthy Volunteers” 
  Lambertville, NJ - 4/8/2009
• Visiting FDA lecturer, “Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome” 
  White Oak, MD - 9/12/2008
• Join now to see all

Other

• Quoted in article "Newborns Hooked on Moms' Painkillers Go Through Agonizing Withdrawal" 
  ABCnews.com
  11/14/2011
• Quoted in "Doctor At Jefferson Works To Speed Up Process Of Weaning Newborns Off Drugs" 
  KYW Newsradio
  11/11/2011
• Quoted in article "Treating the tiniest addicts" 
  The Buffalo News
  6/1/2011
• Quoted in article "Obstructive Sleep Apnea" 
  ACP Hospitalist
  4/1/2011
• Quoted in article “Study Finds Opioid Overdose Incidence Tied to Higher Prescribed Dosages” 
  Pain Medicine News
  4/1/2010
• Acid Peptic Diseases: Pharmacological Approach To Treatment. 
  Kraft WK, Mejia A, Expert Review in Clinical Pharmacology
  1/1/2009
• Aprepitant For The Prevention Of Nausea And Vomiting Associated With Chemotherapy And Postoperative Recovery. 
  LaRusso J, Waldman SA, Kraft WK, Expert Review in Clinical Pharmacology
  1/1/2008
• Bridging the Therapeutic Continuum of Drug Development, Regulation and Use. 
  Kraft WK, Waldman SA, Expert Review in Clinical Pharmacology
  1/1/2008
• The Bronchodilators. 
  Kraft WK, Frick GS, Hospital Practice Pulmonary Board Review
  4/1/2007
• “Managing preoperative medications”. 
  Marian Freedman [author] Steven L Cohn, Walter K. Kraft, Karen F. Mauck [consultants], Patent Care
  10/1/2006
• “Thomas Jefferson University K30 Program Externship: Critical Review of the Medical Literature at The Annals Of Internal Medicine.” 
  Kraft WK, Waldman SA, Weinberg D, Laine C, Clinical Research Perspective
  3/1/2004
• Thomas Jefferson University Self Directed Intranet Module #09: “Evidence-Based Medicine” 
  Kraft WK
• Internet Video Highlighting the Drug Development Process (Clinical Trials) 
  
  http://www.innovation.org/index.cfm/InsideDrugDiscovery
• Join now to see all